150 mg
Trade Name
Ojjaara
Film-coated tablet
Request Type
New Registration
Drug Type
NCE
Approval Date
SFDA Approved Use
Momelotinib is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia, intermediate or high-risk myelofibrosis who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor nave or have been treated with ruxolitinib